TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8398291

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 166
Study: 2427411

Group type: EXPERIMENTAL
Intervention: Pentosan polysulphate (SP54) intravenously and subsequently orally
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group received the infusion solution and vasodilator drugs
Number of subjects: 55
Study: 30766594

Group type: EXPERIMENTAL
Intervention: 100 µg oral clonidine pre‐medication
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 200 µg oral clonidine pre‐medication
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no oral clonidine pre‐medication)
Number of subjects: 108
Study: 27031473

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU/week)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Vitamin D (n=4, ≥60 years)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (n=4, ≥60 years)
Number of subjects: 18
Study: 24980238

Group type: EXPERIMENTAL
Intervention: Cauterization of both distal and proximal nerve stumps (Group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cauterization of only the proximal nerve stump (Group 2)
Number of subjects: 80
Study: 23756400

Group type: EXPERIMENTAL
Intervention: Shiitake mushroom extract (700 mg, two times per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20653494

Group type: EXPERIMENTAL
Intervention: Olanzapine orodispersible tablet (ODT)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Oral conventional tablet (OCT)
Number of subjects: 175
Study: 18408938

Group type: EXPERIMENTAL
Intervention: Pethidine 1 mg/kg (Group I, n = 60)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tramadol 2 mg/kg (Group II, n = 50)
Number of subjects: 110
Study: 17153649

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14555299

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) 2 mg four times daily
Number of subjects: 27
Study: 11009131

Group type: EXPERIMENTAL
Intervention: Church-based health education program for mammography promotion
Number of subjects: 1967

Group type: EXPERIMENTAL
Intervention: Community-based strategies for recruitment
Number of subjects: 1967
Study: 9361692

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy Control
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hypertensive NIDDM
Number of subjects: 25
Study: 1557840

Group type: EXPERIMENTAL
Intervention: Mini-dose heparin
Number of subjects: 68
Study: 3552466

Group type: EXPERIMENTAL
Intervention: Synchronous high-frequency jet ventilation (HFJV)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intermittent positive-pressure breathing (IPPB)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Asynchronous high-frequency jet ventilation (HFJV)
Number of subjects: 9
Study: 29889755

Group type: EXPERIMENTAL
Intervention: Salpingectomy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard Tubal Ligation
Number of subjects: 44
Study: 27821789

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine (SSD)-impregnated hydrocolloid dressing
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hydrocolloid dressing
Number of subjects: 14
Study: 24856872

Group type: EXPERIMENTAL
Intervention: Cholecalciferol, 25,000IU, per week orally for 13 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 23357807

Group type: EXPERIMENTAL
Intervention: NAL-NL2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CAM2
Number of subjects: 14

Group type: COMPARATOR
Intervention: NAL-NL2 and CAM2
Number of subjects: 14
Study: 20963833

Group type: EXPERIMENTAL
Intervention: Nasal high frequency percussive ventilation (NHFPV)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 46
Study: 19549432

Group type: EXPERIMENTAL
Intervention: CIC80 b.i.d.
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: CIC160 q.d.
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: CIC80 b.i.d./CIC160 q.d.
Number of subjects: 711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: CIC treatments (all groups)
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 711
Study: 16401531

Group type: EXPERIMENTAL
Intervention: Training and Support Programme (TSP) - 8 weekly sessions, 1 hour each, teaching massage skills
Number of subjects: 95

Group type: COMPARATOR
Intervention: Waiting-list Control Group
Number of subjects: 95
Study: 15253580

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (Conventional treatment)
Number of subjects: 61
Study: 11568516

Group type: EXPERIMENTAL
Intervention: High lactose formula (HLF)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Low lactose formula (LLF)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Human milk (more than 10%)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Human milk (less than 10%)
Number of subjects: 99
Study: 9709275

Group type: EXPERIMENTAL
Intervention: Single-view mammography screening
Number of subjects: 14842

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 14842
Study: 8104272

Group type: EXPERIMENTAL
Intervention: Regular inhaled salbutamol (200 micrograms four times daily for 2 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (2 weeks)
Number of subjects: 13
Study: 3769482

Group type: EXPERIMENTAL
Intervention: DHPA 150 mg + E2‐EN 10 mg (group I, n = 9)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Half-dose of DHPA + E2‐EN (group II, n = 7)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (group I and group II)
Number of subjects: 16
Study: 29268031

Group type: EXPERIMENTAL
Intervention: 30:240 (n = 11; 4‐6 × 30‐s bouts, 4 min rest)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 15:120 (n = 11; 8‐12 × 15‐s bouts, 2 min rest)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 5:40 (n = 12; 24‐36 × 5‐s bouts, 40 s rest)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-exercising control (n = 9)
Number of subjects: 43
Study: 27297013

Group type: EXPERIMENTAL
Intervention: Routine iron prophylaxis (60 mg ferrous sulfate plus 400 μg folic acid daily)
Number of subjects: 4326

Group type: COMPARATOR
Intervention: Selective iron prophylaxis (1 mg folic acid daily and Hb screening with treatment for low Hb)
Number of subjects: 4326
Study: 24980710

Group type: EXPERIMENTAL
Intervention: Extended therapy (72 weeks of PEG‐IFNα‐2a)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard therapy (48 weeks of PEG‐IFNα‐2a)
Number of subjects: 80
Study: 22476362

Group type: EXPERIMENTAL
Intervention: Internet-based education (experiment)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Face-to-face education with a nurse (control)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Both groups (experiment and control)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Demographic variables
Number of subjects: 147
Study: 20535662

Group type: EXPERIMENTAL
Intervention: Vibration + static stretch group (V)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Static stretch group (SS)
Number of subjects: 34
Study: 18533777

Group type: EXPERIMENTAL
Intervention: Repeated subgingival scaling (test)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Periodontal surgery (control)
Number of subjects: 26
Study: 15948808

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (rabeprazole 20 mg b.d. plus amoxicillin 1 g b.d. for the first 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg and tinidazole 500 mg, all b.d., for the remaining 5 days)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard 7-day triple regimen (rabeprazole 20 mg, clarithromycin 500 mg and amoxicillin 1 g, all b.d.)
Number of subjects: 179
Study: 12783043

Group type: EXPERIMENTAL
Intervention: High-fat diet (53% fat)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-fat diet (17% fat)
Number of subjects: 11
Study: 10482981

Group type: EXPERIMENTAL
Intervention: t(12;21) positive acute lymphoblastic leukemia
Number of subjects: 169
Study: 9772599

Group type: EXPERIMENTAL
Intervention: Wenyang Tongluo Mixture (WYTLM)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Salbutamol orally and beclomethasone dipropionate aerosol
Number of subjects: 68
Study: 1929610

Group type: EXPERIMENTAL
Intervention: Preoperative tune-up using pulmonary artery catheter (PA catheter)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no preoperative tune-up)
Number of subjects: 89
Study: 6615689

Group type: EXPERIMENTAL
Intervention: Meptazinol 400 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Meptazinol 200 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pentazocine 100 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30081658

Group type: EXPERIMENTAL
Intervention: Intracoronary sodium nitrite during primary PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard primary PCI only (placebo)
Number of subjects: 0
Study: 26768003

Group type: EXPERIMENTAL
Intervention: E-learning course in physiotherapy in oncology (PHO)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Traditional classroom course in physiotherapy in oncology (PHO)
Number of subjects: 67
Study: 26681132

Group type: EXPERIMENTAL
Intervention: Cocoa flavanol (CF) ingestion (900 mg CF per study day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 24716412

Group type: EXPERIMENTAL
Intervention: Standard treatment + rhBNP (recombinant human B-type natriuretic peptide) for up to 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhBNP group
Number of subjects: 0
Study: 21965520

Group type: EXPERIMENTAL
Intervention: Perceptive rehabilitation (10 sessions in one month)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Back School programme
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (medical and pharmacological assistance)
Number of subjects: 75
Study: 19237881

Group type: EXPERIMENTAL
Intervention: Hemofiltration (25 mL/kg/hr) for a 96-hour period
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional management (Control group)
Number of subjects: 80
Study: 17228672

Group type: EXPERIMENTAL
Intervention: Intraoperative X-ray imaging (Group I)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard THA method (Group S)
Number of subjects: 141
Study: 15689054

Group type: EXPERIMENTAL
Intervention: Novel polyherbal formulation (PF; Aller‐7/NR‐A2)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 545
Study: 11705489

Group type: EXPERIMENTAL
Intervention: Imatinib at a dose of 500 mg twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Imatinib at a dose of 400 mg twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Imatinib (various doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PET scan responses
Number of subjects: 40
Study: 9279340

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 7993413

Group type: EXPERIMENTAL
Intervention: Intravenous dobutamine (5 to 200 micrograms per kilogram of body weight per minute)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (dobutamine administered only if cardiac index was below 2.8 liters per minute per square meter)
Number of subjects: 109
Study: 3281701

Group type: EXPERIMENTAL
Intervention: Clonidine 0.6 mg by mouth 2 h before operation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 20
Study: 29453232

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) 1,000 mg by mouth twice daily for 12 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 29141061

Group type: EXPERIMENTAL
Intervention: HQ-free system
Number of subjects: 30

Group type: COMPARATOR
Intervention: HQ-based system
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 30
Study: 26315284

Group type: EXPERIMENTAL
Intervention: Integrated Management of Infectious Disease (IMID) training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: On-site support (OSS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no OSS)
Number of subjects: 36
Study: 23833564

Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg/kg IV every 3 weeks for up to 4 doses)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Dacarbazine (850 mg/m2 IV every 3 weeks)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel (Paclitaxel 175 mg/m2 IV and Carboplatin [AUC=6] IV every 3 weeks)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ipilimumab maintenance (10 mg/kg every 12 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ipilimumab with Dacarbazine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ipilimumab with Carboplatin/Paclitaxel
Number of subjects: 59
Study: 21545273

Group type: EXPERIMENTAL
Intervention: Pumpkin seed oil (n = 21)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Wheat germ oil (placebo; n = 14)
Number of subjects: 35
Study: 18438267

Group type: EXPERIMENTAL
Intervention: Epinephrine 1:100,000 and lidocaine 1%
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 22
Study: 15374698

Group type: EXPERIMENTAL
Intervention: Urinary FSH
Number of subjects: 67

Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 67
Study: 11583471

Group type: EXPERIMENTAL
Intervention: ketoconazole (three 200 mg doses spaced 12 hours apart)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control condition (no ketoconazole)
Number of subjects: 8
Study: 9630408

Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Netivudine
Number of subjects: 511
Study: 8015061

Group type: EXPERIMENTAL
Intervention: ESWL in situ
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pre-ESWL stone manipulation
Number of subjects: 70
Study: 2643751

Group type: EXPERIMENTAL
Intervention: Bezafibrate alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bezafibrate and cholestyramine combined
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cholestyramine
Number of subjects: 21
Study: 1099860

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam intravenously as preoperative sedative
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 30755274

Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse laser
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard threshold laser
Number of subjects: 0
Study: 28236077

Group type: EXPERIMENTAL
Intervention: TeleCARE (remote, tailored‐risk communication intervention)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Mailed educational brochure intervention
Number of subjects: 481
Study: 25929392

Group type: EXPERIMENTAL
Intervention: Protein Diet (PD)
Number of subjects: 32
Study: 23760281

Group type: EXPERIMENTAL
Intervention: Predictable scaling of ID (decreasing from high 6.5 to low 2.5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random ID presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Constant ID presentation
Number of subjects: 0
Study: 21537559

Group type: EXPERIMENTAL
Intervention: Migraine children
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 19309327

Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community sample
Number of subjects: 0
Study: 16782099

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Preoperative MR imaging
Number of subjects: 53
Study: 15175486

Group type: EXPERIMENTAL
Intervention: Verbal descriptors (e.g., 'common' for constipation, 'rare' for pancreatitis)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Numerical descriptors (e.g., 2.5% for constipation, 0.04% for pancreatitis)
Number of subjects: 120
Study: 11672493

Group type: EXPERIMENTAL
Intervention: Dexamphetamine (up to 60 mg daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Counselling (weekly)
Number of subjects: 41
Study: 9234826

Group type: EXPERIMENTAL
Intervention: 50-min treadmill walk at 50% VO2max
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nonexercise control day
Number of subjects: 61
Study: 8306143

Group type: EXPERIMENTAL
Intervention: Intermittently closed drainage systems
Number of subjects: 40

Group type: COMPARATOR
Intervention: Permanently closed drainage systems
Number of subjects: 40
Study: 3450328

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive training (IRT) with a P Flex device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional breathing retraining (BR)
Number of subjects: 20
Study: 30318837

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g·kg‐1 body mass)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 0.2 g·kg‐1 body mass)
Number of subjects: 8
Study: 26135690

Group type: EXPERIMENTAL
Intervention: Pancreatogastrostomy (PG)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Pancreatojejunostomy (PJ)
Number of subjects: 440
Study: 24196543

Group type: EXPERIMENTAL
Intervention: Minilaparotomy (MC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 48
Study: 22125197

Group type: EXPERIMENTAL
Intervention: Cold polypectomy for <10-mm polyps
Number of subjects: 823
Study: 19896801

Group type: EXPERIMENTAL
Intervention: hylan G-F 20
Number of subjects: 0

Group type: COMPARATOR
Intervention: appropriate care
Number of subjects: 0
Study: 18303254

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (75 mg/day plus 75-162 mg/day)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 593
Study: 16291412

Group type: EXPERIMENTAL
Intervention: Topical ketotifen fumarate 0.025% ophthalmic solution
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Topical olopatadine HCl 0.1% ophthalmic solution
Number of subjects: 39

Group type: COMPARATOR
Intervention: Artificial tear substitute (ATS)
Number of subjects: 39
Study: 12145231

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg (acute effect)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg (prolonged effect after 2 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (acute effect)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (prolonged effect after 2 weeks)
Number of subjects: 16
Study: 10211849

Group type: EXPERIMENTAL
Intervention: Intermittent high intensity exercise (HIGH) - 60 min alternating 5 min running at approximately 90% of VO2max with 5 min brisk walking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous moderate intensity exercise (MOD) - 60 min continuous run at 60% of VO2max
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rest (REST)
Number of subjects: 0
Study: 7614527

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily, up to 50 mg if needed) plus hydrochlorothiazide (HCTZ)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Digoxin (0.1 mg twice daily) plus hydrochlorothiazide (HCTZ)
Number of subjects: 116
Study: 2393281

Group type: EXPERIMENTAL
Intervention: Cefprozil 250 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefprozil 1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefaclor 500 mg
Number of subjects: 0
Study: 57340

Group type: EXPERIMENTAL
Intervention: High doses of steroid drugs plus 600 rads of radiotherapy to the graft
Number of subjects: 36

Group type: COMPARATOR
Intervention: High doses of steroid drugs
Number of subjects: 36
Study: 31215985

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 1746

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 1746
Study: 29067950

Group type: EXPERIMENTAL
Intervention: Robot-assisted SI screw fixation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Freehand SI screw fixation
Number of subjects: 30
Study: 26220326

Group type: EXPERIMENTAL
Intervention: Individually-defined therapy program (IT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General therapy program (GT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both IT and GT programs
Number of subjects: 40
Study: 23066649

Group type: EXPERIMENTAL
Intervention: Mindfulness centering exercise (5 minutes before session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No mindfulness centering exercise (control group)
Number of subjects: 0
Study: 21584908

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 7